Real-World EQ5D Health Utility Scores for Metastatic Lung Cancer Patients by Molecular Alteration and Response to Therapy

There is limited data outside of clinical trials on health utility scores (HUS) in metastatic lung cancer patients. This longitudinal cohort study evaluated EQ5D-3L-derived HUS in 475 outpatients. Mean scores were higher in patients carrying driver mutations stable on targeted treatments, than in patients without alterations stable on chemotherapy. Such differences should be considered in economic analyses of upcoming treatments.

from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2iQDtoc
via IFTTT